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Comparison of Early and Late Conversion of Sirolimus  
in Experimental Model of Chronic Cyclosporine Nephropathy
Sirolimus (SRL) is a promising drug for replacing calcineurin inhibitors. We performed this 
study to determine the optimal time of conversion from cyclosporine (CsA) to SRL in an 
experimental model of chronic CsA nephropathy. Three separate studies were performed. 
In the first study, SRL was given to rats with or without CsA for 4 weeks. In the second 
study, rats were treated initially with CsA for 1 week, and then switched to SRL (early 
conversion). In the third study, CsA was given for 4 weeks and then replaced by SRL for  
4 weeks treatment of CsA (late conversion). The influence of SRL on CsA-induced renal 
injury was evaluated by assessing renal function, histopathology (interstitial inflammation 
and fibrosis), and apoptotic cell death. Combined CsA and SRL treatment significantly 
impaired renal function, increased apoptosis, and interstitial fibrosis and inflammation 
compared with CsA or SRL treatment alone. Early conversion to SRL did not change renal 
function, histopathology, or apoptosis compared with early CsA withdrawal. By contrast, 
late conversion to SRL significantly aggravated these parameters compared with late CsA 
withdrawal. In conclusion, early conversion from CsA to SRL is effective in preventing CsA-
induced renal injury in a setting of CsA-induced renal injury.
Key Words: Cyclosporine; Conversion; Nephrotoxicity; Sirolimus
Jin Young Kim
1,*, Jung Yeon Ghee
1,*, 
Sun Woo Lim
1, Shang Guo Piao
1, 
Byung Ha Chung
1, Hye Eun Yoon
1, 
Hyeon Seok Hwang
1, Bum Soon Choi
1, 
Jin Kim
2, and Chul Woo Yang
1,2
1Transplant Research Center, Convergent Research 
Consortium for Immunologic Disease; 
2Cell Death 
Disease Research Center, Department of Anatomy, 
The Catholic University of Korea, Seoul, Korea
*Jin Young Kim and Jung Yeon Ghee contributed 
equally to this work.
Received: 1 June 2011
Accepted: 21 November 2011
Address for Correspondence:
Chul Woo Yang, MD 
Department of Internal Medicine, Seoul St. Mary’s Hospital,  
The Catholic University of Korea, 222 Banpodae-ro, Seocho-gu,  
Seoul 137-040, Korea 
Tel: +82.2-590-2527, Fax: +82.2-536-0323
E-mail: yangch@catholic.ac.kr
This study was supported by a grant of the Korea Healthcare 
Technology R&D project, Ministry for Health & Welfare Affairs, 
Republic of Korea (A092258).
http://dx.doi.org/10.3346/jkms.2012.27.2.160  •  J Korean Med Sci 2012; 27: 160-169
ORIGINAL ARTICLE
Nephrology
INTRODUCTION
Sirolimus (SRL) is a promising maintenance immunosuppres-
sive agent for replacing calcineurin inhibitors (CNI) (1-4). SRL 
itself does not cause severe nephrotoxicity, but combined SRL 
and CNI treatment causes significant nephrotoxicity in most 
animal and human studies (4-8). There is an emerging consen-
sus that conversion from a CNI to SRL is an effective strategy for 
reducing CNI-induced nephrotoxicity.
  Clinical trials of SRL show that early conversion to SRL is ef-
fective in preserving graft function and that late conversion in 
recipients with poor graft function or proteinuria does not pro-
vide beneficial effects on graft function (9, 10). Therefore, early 
conversion to SRL after transplantation is recommended, but 
the optimal time for conversion has not been determined. It is 
also unclear whether the undesirable effects of late conversion 
to SRL are related to the preexisting CNI-induced renal injury 
or to the effect of SRL itself.
  In this study, we focused on the influence of SRL on Cyclo-
sporine (CsA)-induced renal injury. To evaluate the optimal 
time for conversion, we compared the influence of early and 
late conversion from CsA to SRL on CsA-induced renal injury in 
an experimental model of chronic CsA-nephrotoxicity. The re-
sults of our study show clearly that early conversion from CsA 
to SRL is effective in preventing CsA-induced renal injury in an 
experimental setting of CsA-induced renal injury. 
MATERIALS AND METHODS 
Animals and drugs 
The institutional animal care and use committee of the Catholic 
University of Korea approved the experimental protocol (CUMC-
2008-0075-01), and all procedures performed in this study fol-
lowed the ethical guidelines for animal studies. Male Sprague 
Dawley rats (Charles River Technology, Seoul, Korea), initially 
weighing 230 to 250 g, were housed in cages (Nalge Co., Roch-
ester, NY, USA) in a controlled-temperature and controlled-light 
environment, and were allowed free access to a low salt diet 
(0.05% sodium, Teklad Premier, Madison, WI, USA) throughout 
the experimental period. After starting the treatment, the rats 
were pair-fed and daily body weight (BW) was monitored. Ani-
mals were anesthetized with ketamine. CsA (Novartis Pharma Kim JY, et al.  •  Effect of Sirolimus on CsA-induced Nephrotoxicity
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Ltd, Basel, Switzerland) was diluted in olive oil (Sigma Co., St 
Louis, MO, USA) to a final concentration of 15 mg/mL. SRL 
(Wyeth-Ayerst Research, Princeton, NJ, USA) was dissolved in 
solution of Tween 80 (10%), N, N-dimethylacetamide (20%), 
and polyethylene glycol 400 (70%), to a final concentration of 
0.3 mg/mL.
Experimental design
Three separate experiments were performed, as shown Fig. 1. 
  Experiment I: This experiment was designed to evaluate the 
influence of the combined treatment of SRL and CsA on CsA-
induced nephrotoxicity. 
  Rats were randomized to four groups and treated for 4 weeks.
1) Vehicle group (VH4, n = 7): rats received a daily subcuta-
neous injection of olive oil (1 mL/kg) for 4 weeks.
2) VH4 + SRL4 group (n = 7): rats received a daily subcuta-
neous injection of olive oil and SRL (0.3 mg/kg) for 4 weeks.
3) CsA4 group (n = 7): rats received a daily subcutaneous 
injection of CsA (15 mg/kg) for 4 weeks.
4) CsA4 + SRL4 group (n = 7): rats received a daily subcuta-
neous injection of CsA and SRL (0.3 mg/kg) for 4 weeks. 
  Experiment II: This experiment was designed to evaluate the 
effect of early conversion from CsA to SLR on CsA-induced neph-
rotoxicity. 
  Rats were randomized to four groups and treated for 4 weeks.
1) VH1 + W3 group (n = 7): rats received olive oil for 1 week, 
after which olive oil was withheld for 3 weeks.
2) VH1 + SRL3 group (n = 7): rats received VH for 1 week 
and then SRL for 3 weeks.
3) CsA1 + W3 group (n = 7): rats received CsA for 1 week, after 
which CsA was withheld for 3 weeks.
4) CsA1 + SRL3 group (n = 7): rats received CsA for 1 week 
and then SRL for 3 weeks. 
  Experiment III: This experiment was designed to evaluate the 
effect of late conversion from CsA to SRL in established chronic 
CsA nephropathy. 
  Rats were randomized to four groups and treated for 4 or   
      8 weeks: 
1) VH4 + W4 group (n = 7): rats received a daily subcutane-
ous injection of olive oil for 4 weeks, after which olive oil 
was withheld for 4 weeks.
2) VH4 + SRL4 group (n = 7): rats received a daily subcuta-
neous injection of olive oil for 4 weeks, and then SRL for 
4 weeks.
3) CsA4 + W4 group (n = 7): rats received a daily subcutane-
ous injection of CsA for 4 weeks, after which the CsA was 
withheld for 4 weeks.
4) CsA4 + SRL4 group (n = 7): rats received a daily subcuta-
neous injection of CsA for 4 weeks, and then SRL for 4 
weeks.
  The doses and duration of administration of the vehicle (Olive 
Fig. 1. Experimental design. Three separate studies were performed. (A) Combined sirolimus and cyclosporine, (B) early conversion, and (C) late conversion. S.C., subcutaneous 
injection; VH, vehicle.
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oil; 1 mL/kg), CsA (15 mg/kg), and SRL (0.3 mg/kg) were cho-
sen based on previous reports (5, 11, 12).
Measurement of renal function and whole blood CsA and 
SRL levels
Serum creatinine (SCr) concentration was measured using a 
Cobas autoanalyzer (Roche Diagnotics, Division of Hoffman-
La Roche Inc., Nutley, NJ, USA). Whole-blood CsA level was 
measured using a monoclonal radioimmunoassay (INSCTART 
Corp., Stillwater, MN, USA), and whole-blood SRL concentra-
tion was measured using a microparticle enzyme immunoas-
say (Abbott Diagnostics, Abbott Park, IL, USA).
Preservation of kidney
The kidneys were preserved by in vivo perfusion through the 
abdominal aorta. In brief, the animals were perfused with 0.01 
M phosphate-buffered saline (PBS) to wash out the blood. The 
left kidney was removed for immunoblotting analysis or RNA 
extraction and the right kidney was removed after perfusion 
with the periodate–lysine–paraformaldehyde (PLP) solution for 
4 min. The kidneys were removed and cut into sagittal slices of 
1-2 mm thickness and post-fixed overnight in PLP solution at 
4°C. A part of the PLP-fixed tissues was embedded in wax for 
trichrome staining. After dewaxing, 4-μm sections were pro-
cessed and stained with Masson’s trichrome stain. 
Measurement of interstitial fibrosis 
To assess interstitial fibrosis, kidney paraffin sections were stained 
with Masson’s trichrome stain. Tubulointerstitial fibrosis (TIF) 
was identified using the definition described previously (13). 
Briefly, a minimum of 20 fields per section was assessed using a 
color image analyzer (TDI Scope EyeTM Version 3.0 for Win-
dows, Olympus, Tokyo, Japan). Randomly selected cortical fields 
of sections were analyzed histopathologically by two patholo-
gists blinded to the identity of the treatment groups.
Immunohistochemistry of osteopontin (OPN) and ED-1
After dewaxing, sections were incubated with 0.5% Triton X 
100/PBS solution and washed with PBS, and then incubated for 
2 hr at 4°C in mouse antiserum against OPN (MPIIIB10, obtained 
from the Developmental Studies Hybridoma Bank, University 
of Iowa, Iowa City, IA, USA) and ED-1 (Serotec Inc., Oxford, UK). 
The number of ED-1-positive cells was quantified per 0.5 mm
2 
area of rat kidney using a computer program (TDI Scope Eye 
Version 3.0 for Windows, Olympus). A minimum of 20 fields 
per section were assessed. 
Immunoblotting of active caspase-3 
Western blot analysis was performed as described previously 
(13). Active caspase-3 was detected by incubating for 1 hr with 
a specific antibody (Chemicon International, Inc., MA, USA). 
Antibody-reactive protein was detected using enhanced che-
miluminescence (ECL, Amersham Biosciences, Little Chalfont, 
UK). Optical density was measured using the VH group as 100% 
reference and normalized by β-actin.
Northern blot analysis of OPN 
Northern blotting was performed as described previously by 
our laboratory (11). The densitometric analysis was performed 
using the NIH ImagePC program for three determinations for 
each band, and the results were corrected to 18S. 
Terminal deoxynucleotidyl transferase dUTP nick end 
labeling (TUNEL) staining
Cells undergoing apoptosis were identified by the ApopTag in 
situ apoptosis detection kit (Oncor Inc., Gaithersburg, MD, USA). 
The number of TUNEL-positive cells was counted in 20 differ-
ent fields in each section under  × 200 magnification (13, 14).
Statistical analysis
The data are expressed as mean ± SEM. Multiple comparisons 
between groups were performed using one-way analysis of vari-
ance followed by Bonferroni post hoc testing (SPSS software 
version 9.0). Significance was assumed as P < 0.05.
 
RESULTS
Effect of combined treatment with SRL and CsA on chronic 
CsA nephropathy
Table 1 shows the basic parameters for the first experimental 
group. After 4 weeks, the CsA group showed deterioration of re-
nal function, as shown by an increase in SCr concentration com-
Table 1. Effect of combined CsA and SRL treatment on basic parameters
Parameters     VH4       VH4 + SRL4    CsA4     CsA4 + SRL4
BW (g) 327 ± 6 284 ± 4 314 ± 7  228 ± 4
†
SCr conc (mg/dL)     0.51 ± 0.09     0.44 ± 0.13      0.98 ± 0.03*        1.21 ± 0.04*,†
Water intake (mL/day)   16 ± 2    27 ± 3*   14 ± 2    59 ± 6
†
Urine volume (mL/day)   14 ± 4    28 ± 4*   15 ± 2    60 ± 7
†
CsA conc (ng/mL) - - 2047 ± 63 1989 ± 69
SRL conc (ng/mL) -   12.2 ± 1.1   -   14.2 ± 1.6
Values are means ± SE. *P < 0.01 vs VH; 
†P < 0.05 vs CsA group. BW, body weight; SCr conc, serum creatinine concentration; CsA conc, cyclosporine concentration. SRL conc, 
sirolimus concentration. Kim JY, et al.  •  Effect of Sirolimus on CsA-induced Nephrotoxicity
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pared with the VH4 and VH4 + SRL4 groups (P < 0.05). As ex-
pected, the combined CsA and SRL treatment significantly im-
paired renal function compared with the other groups (P < 0.05). 
  Kidney tissues from CsA-treated rats had typical striped in-
terstitial fibrosis. Tissues from rats treated with combined CsA4 
and SRL4 showed more interstitial fibrosis (39 ± 4/0.5 mm
2) com-
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Fig. 2. Influence of combined treatment of SRL and CsA on interstitial fibrosis in chronic CsA nephropathy. (A) Trichrome staining. The CsA group shows typical striped intersti-
tial fibrosis in the cortex whereas the VH4 and VH4 + SRL4 groups does not show any change. The CsA4 + SRL4 group shows further interstitial fibrosis compared with the 
CsA4 and VH4 + SRL4 groups (original magnification, × 200). (B) Quantitative analysis of TIF. Note the markedly greater interstitial fibrosis in the CsA4 + SRL4 group compared 
with the CsA4 and VH4 + SRL4 groups. *P < 0.01 vs VH4 or VH4 + SRL4 groups; 
†P < 0.01 vs CsA4 group. 
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Fig. 3. Influence of combined SRL and CsA treatment on interstitial inflammation in chronic CsA nephropathy. (A) ED-1 immunohistochemistry. (B) Quantitative analysis of ED-1 
positive cells. Note the significantly higher number of ED-1-positive cells in the CsA4 + SRL4 group than the CsA4 group. *P < 0.01 vs VH4 or VH4 + SRL4 groups; 
†P < 0.05 
vs CsA4 group. (C) Immunohistochemistry of OPN protein. (D) Northern blot analysis for osteopontin (OPN) mRNA. Note the greater OPN mRNA expression in the CsA4 + SRL4 
group compared with the CsA4 and VH4 + SRL4 groups. The data are presented as relative optical density with the VH4 group designated as 100% reference and are normal-
ized to 18S. *P < 0.01 vs VH4 or VH4 + SRL4 groups; 
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pared with tissues from rats treated with SRL alone (0.1 ± 0.04/ 
0.5 mm
2) and CsA alone (24 ± 0.8/0.5 mm
2) (P < 0.01, Fig. 2). 
  We used immunohistochemistry to stain for ED-1 to detect 
macrophage infiltration in this chronic CsA nephropathy model 
(13, 14). As shown in Fig. 3A, ED-1-positive cells were observed 
rarely in the VH4 and VH4 + SRL4 groups. More ED-1-positive 
cells (68 ± 7/mm
2) were observed in kidneys from the CsA4 
group than from the VH4 group (14 ± 2/mm
2), and VH4 + SRL4 
group (15 ± 1/mm
2) (P < 0.01). The highest number of ED-1-
positive cells was observed in the CsA4 + SRL4 group compared 
with CsA4 group (89 ± 5/mm
2, P < 0.05). 
  We used Northern blot analysis to measure the mRNA expres-
sion for OPN, a proinflammatory cytokine in animal models of 
CsA-induced renal injury (15, 16). OPN mRNA was expressed 
minimally in the kidneys of the VH4 and VH4 + SRL4 groups. 
The expression of OPN mRNA was significantly higher in the 
CsA4 group (1,987% ± 179%) than in the VH4 group (100% ±  
0.4%) and VH4 + SRL4 group (103% ± 3%) (P < 0.01 for the CsA4 
group compared with other two groups). OPN mRNA expres-
sion was much higher in the CsA4 + SRL4 group (3,315% ± 361%) 
than in the VH4, VH4 + SRL4 (P < 0.01), and CsA4 groups (P <  
0.05, Fig. 3D). OPN protein expression followed a similar pattern 
(Fig. 3C). 
  We used TUNEL staining and active caspase-3 expression for 
evaluation of apoptotic cell death, one of the mechanisms in-
volved in the injury and repair process in the chronic CsA neph-
rotoxicity model (17). Treatment with VH or SRL did not affect 
TUNEL-positive cells, which were observed rarely in the VH4 
and VH4 + SRL4 groups (11 ± 0.7/0.5 mm
2 and 12 ± 0.5/0.5 mm
2, 
respectively). However, the number of TUNEL-positive cells was 
higher in the CsA4 group (54 ± 2/0.5 mm
2, P < 0.01 vs VH4 or 
VH4 + SRL4 groups), and even higher in the CsA4 + SRL4 group. 
(84 ± 2/0.5 mm
2, P < 0.01 vs VH4 or VH4 + SRL4; P < 0.05 vs CsA4, 
Fig. 4A, B), Immunoblotting analysis of the kidney showed a sig-
nificant increase in active caspase-3 in the CsA4 group (3,541% 
± 473%) compared with the VH4 (103% ± 11%) and VH4 + SRL4 
group (105% ± 9%) (P < 0.01 for the CsA4 group compared with 
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Fig. 4. Influence of combined of SRL and CsA treatment on apoptotic cell 
death in chronic CsA nephropathy. (A) Representative photomicrographs of 
the TUNEL assay (original magnification, × 200). Arrows indicate the TUNEL-
positive cells. (B) Quantitative analysis of TUNEL-positive cells. Note that 
the number of TUNEL-positive cells was higher in the CsA4 + SRL4 group 
compared with the CsA4 and VH4 + SRL4 groups. (C) Immunoblots for ac-
tive caspase-3. Active caspase-3 protein levels are referenced against 
β-actin and the relative optical density is presented with the VH4 group 
designated as 100% reference and normalized with β-actin. * P < 0.01 vs 
VH4 or VH4 + SRL4 group; 
†P < 0.05 vs CsA4 group. C
Table 2. Effect of early conversion to SRL on basic parameters
Parameters VH1 + W3 VH1 + SRL3   CsA1 + W3 CsA1 + SRL3
BW (g)  280 ± 3  272 ± 2  277 ± 7  253 ± 5*,†
SCr conc (mg/dL) 0.48 ± 0.09 0.44 ± 0.09 0.50 ± 0.03 0.53 ± 0.04
Water intake  
   (mL/day)
   15 ± 2    27 ± 3    14 ± 2    39 ± 6*,†
Urine volume  
   (mL/day)
   11 ± 3    16 ± 1    11 ± 2    36 ± 4*,†
SRL conc (ng/mL)         -   9.0 ± 2.2         - 11.2 ± 1.2
Values are means ± SE. *P < 0.01 vs VH1 + W3 or CsA1 + W3 group; 
†P < 0.05 vs 
VH1 + SRL3 group. BW, body weight; SCr conc, serum creatinine concentration; SRL 
conc, sirolimus concentration. Kim JY, et al.  •  Effect of Sirolimus on CsA-induced Nephrotoxicity
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the other two groups). The expression of active caspase-3 was 
upregulated more in the CsA4 + SRL4 group (5,625% ± 473%) 
than in the CsA4 group (P < 0.05, Fig. 4C).
Effect of early conversion on CsA-induced renal injury
Table 2 shows the effect of early conversion from CsA to SRL   
on CsA-induced renal injury. Renal function did not differ be-
tween CsA early withdrawal (CsA1 + W3 group) and early con-
version (CsA1 + SRL3) groups. As shown in Fig. 5, the number 
of ED-1 positive cells, OPN mRNA and TIF score did not differ 
between CsA1 + W3 and CsA1 + SRL3 groups. Fig. 6 shows the 
number of TUNEL-positive cells and active caspase-3 expres-
sion in each experimental group. As expected, the number of 
TUNEL-positive cells and active caspase-3 expression did not 
differ significantly between CsA1 + W3 and CsA1 + SRL3 groups. 
Effect of late conversion on progression of chronic CsA 
nephropathy
Table 3 shows the effect of late conversion from CsA to SRL on 
the progression of chronic CsA nephropathy. Renal function was 
normalized after CsA withdrawal (CsA4 + W4 group), but late 
conversion of SRL (CsA4 + SRL4 group) caused deterioration of 
renal function as compared with the other groups (P < 0.05). 
  Fig. 7 shows the number of ED-1-positive cells in the experi-
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Table 3. Effect of late conversion of SRL on basic parameters
Parameters   VH4 + W4  VH4 + SRL4  CsA4 + W4  CsA4 + SRL4
BW (g)  287 ± 10  273 ± 10  287 ± 10   280 ± 4
SCr conc (mg/dL) 0.69 ± 0.08 0.65 ± 0.04 0.41 ± 0.05  0.85 ± 0.38*
Water intake  
   (mL/day)
22.6 ± 4.8 21.7 ± 5.4 23.7 ± 5.6  24.5 ± 3.1
Urine volume  
   (mL/day)
13.3 ± 2.5 13.0 ± 4.2 11.7 ± 2.0  12.3 ± 1.9
SRL conc (ng/mL)      -   9.6 ± 1.2      -    7.2 ± 2.2*
Values are means ± SE. *P < 0.05 vs VH4 + W4, VH4 + SRL4, or CsA4 + W4 
group. BW, body weight; SCr conc, serum creatinine concentration; SRL conc, siroli-
mus concentration. 
Fig. 5. Effect of early conversion from CsA to SRL on interstitial inflammation and fibrosis. (A) Quantitative analysis of ED-1-positive cells. There was no difference for the num-
ber of ED-1-positive cells between the CsA early withdrawal and early conversion groups. (B) Northern blotting for OPN mRNA. OPN mRNA did not differ between the early con-
version and the CsA-early withdrawal groups. The data are presented as relative optical densities with the VH1 + W3 group designated as 100% reference and are normalized 
to 18S. (C) Quantitative analysis of TIF. The CsA early withdrawal group shows minimal striped interstitial fibrosis in the cortex. The amount of interstitial fibrosis does not differ 
between the CsA early withdrawal and early conversion groups. 
mental groups. The number of ED-1-positive cells was signifi-
cantly higher in the CsA4 + W4 group (10 ± 1/0.5 mm
2) than the 
VH4 + W4 group (0.6 ± 0.1/0.5 mm
2) and VH4 + SRL4 group 
(0.6 ± 0.1/0.5 mm
2) (P < 0.01 for CsA4 + W4 compared with 
other two groups). Switching CsA to SRL after 4 weeks increased 
the number of ED-1- positive cells to 32 ± 5/0.5 mm
2 (P < 0.01). 
Northern blot analysis showed a significantly greater OPN mRNA 
expression in the CsA4 + W4 group (151% ± 17%) compared with 
the VH4 + W4 (128% ± 28%) and VH4 + SRL4 groups (89% ± 35%) 
(P < 0.01 for the CsA4 + W4 compared with the two other groups). 
OPN mRNA expression was the highest in the late conversion 
from CsA to SRL (CsA4 + SRL4) group (691% ± 510%, P < 0.01 Kim JY, et al.  •  Effect of Sirolimus on CsA-induced Nephrotoxicity
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compared with the CsA4 + W4 group, Fig. 7B). 
  The TIF score was higher in the CsA4 + W4 group (7.6 ± 1.1/ 
Fig. 7. Effect of late conversion from CsA to SRL on interstitial inflammation and fibrosis. (A) Quantitative analysis of ED-1-positive cells. The number of ED-1-positive cells is 
high in the CsA4 + W4 group compared with the VH4 + W4 group or the VH4 + SRL4 group. Late conversion from CsA to SRL at 4 weeks further increases the number of ED-
1-positive cells compared with the CsA late withdrawal group. (B) Northern blotting for OPN mRNA. Late conversion from CsA to SRL significantly increases OPN mRNA expres-
sion in the CsA late withdrawal rat kidney. The data are presented as relative optical density with the VH4 + W4 group designated as 100% reference and are normalized to 
18S. *P < 0.01 vs VH4 + W4 or VH4 + SRL4 group; 
†P < 0.05 vs CsA4 + W4 group. (C) Quantitative analysis of TIF. Late conversion from CsA to SRL causes greater interstitial 
fibrosis than that observed in the CsA late withdrawal group. *P < 0.01 vs VH4 + W4 or VH4 + SRL4 groups; 
†P < 0.05 vs CsA4 + W4 group. 
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0.5 mm
2) compared with the VH4 + W4 (1.8 ± 0.3/0.5 mm
2) or 
VH4 + SRL4 groups (1.7 ± 0.5/0.5 mm
2, P < 0.01 for the CsA4 + Kim JY, et al.  •  Effect of Sirolimus on CsA-induced Nephrotoxicity
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W4 group compared with the two other groups). The TIF score 
was highest in the late conversion from CsA to SRL group (16 ± 1/ 
0.5 mm
2) than in the CsA4 + W4 group (7.6 ± 1.1/0.5 mm
2, P <  
0.01, Fig. 7C). 
  Fig. 8A shows the number of TUNEL-positive cells in each 
experimental group. The number of TUNEL-positive cells was 
significantly higher in the CsA4 + W4 group (24 ± 2/0.5 mm
2) 
compared with the VH4 + W4 group (4 ± 0.6/0.5 mm
2) and VH4 
+ SRL4 group (4 ± 0.9/0.5 mm
2, P < 0.01 for the CsA4 + W4 group 
compared with the two other groups). The number of apoptotic 
cells was even higher in the late conversion from CsA to SRL 
group (89 ± 3/0.5 mm
2, P < 0.05 compared with the CsA4 + W4 
group). Active caspase-3 protein levels were significantly higher 
in the CsA4 + W4 group (407% ± 70%) than the VH4 + W4 group 
(105% ± 5%) and the VH4 + SRL4 groups (115% ± 10%) (P < 0.01 
for the CsA4 + W4 group compared with the two other groups). 
Active caspase-3 protein level was higher in the CsA4 + SRL4 
group (1,029% ± 71%) compared with the CsA4 + W4 group 
(407% ± 70%, P < 0.05, Fig. 8B).
DISCUSSION
Our study was performed to determine optimal timing of con-
version from CsA to SRL in experimental model of chronic CsA 
nephropathy. The results of our study demonstrate clearly that 
early conversion to SRL attenuates the progression of CsA-in-
duced renal injury, whereas late conversion to SRL does not 
provide beneficial effects. This finding suggests that the conver-
sion from SRL to CsA should occur as early as possible, before 
the development of chronic renal injury by CsA. 
  SRL by itself does not cause serious renal injury, but combined 
SRL and CsA treatment has a synergic effect on the development 
of chronic CsA nephrotoxicity (4-8). We first tested whether our 
experimental model of chronic CsA nephropathy produces sim-
ilar results to those observed in clinical studies. SRL treatment 
alone did not induce significant nephrotoxicity but co-adminis-
tration of CsA and SRL exacerbated CsA-induced renal injury. 
These results are consistent with the results of clinical studies, 
indicating that our model is suitable for studying SRL conversion. 
  To determine the optimal timing for conversion from CsA to 
SRL, we compared the effect of early and late conversion to SRL 
on CsA-induced renal injury. We chose day 7 as the time for 
early conversion and day 28 as the time for late conversion be-
cause CsA treatment for 4 weeks in our model induces renal 
dysfunction and chronic changes in kidney, whereas CsA treat-
ment for 1 week causes minimal changes in renal function and 
histology (18, 19). In our current study, early conversion from 
CsA to SRL did not cause further significant changes in renal 
functional or histology alterations compared with the early CsA 
withdrawal group. By contrast, late conversion from CsA to SRL 
did not improve renal function and histopathology (9, 10). Ac-
tually, late conversion to SRL aggravated CsA-induced renal in-
jury, as shown by a significant increase in interstitial inflamma-
tion and fibrosis, even after CsA withdrawal. This finding implies 
that the severity of CsA-induced renal injury is an important 
factor in the successful conversion to SRL. 
  A CONVERT study is to evaluate the effect of conversion from 
CsA to SRL at different time points after transplantation (6-120 
months) (9), and the effect of SRL conversion was evaluated in 
terms of graft function or degree of proteinuria. Our experimen-
Fig. 8. Effect of late conversion from CsA to SRL apoptotic cell death. (A) Quantitative analysis of TUNEL-positive cells. The number of TUNEL-positive cells is much higher in 
the later conversion group than in the CsA-late withdrawal group. (B) Immunoblot analysis of active caspase-3. Note the further increase in active caspase-3 protein level in the 
late conversion group. Active caspase-3 protein levels were referenced against β-actin and the relative optical density was presented with the VH4 + 4W group designated as 
100% reference and normalized with β-actin. *P < 0.01 vs VH4 + W4 or VH4 + SRL4 groups; 
†P < 0.05 vs CsA4 + W4 group.
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tal study is similar to CONVERT study in the point that SRL was 
directly converted from CsA at different stage (early and late) of 
CsA-induced renal injury. The results of CONVERT study showed 
clearly that SRL conversion is beneficial in patients with pre-
served graft function (baseline glomerular filtration rate more 
than 40 mL/min) but not in patients with a severely injured re-
nal allograft. The results of our study were similar to those of 
CONVERT study. Early conversion of SRL before development 
of chronic change by CsA was effective in preventing CsA-in-
duced renal injury but late conversion of SRL in established 
chronic CsA nephropathy failed to improve CsA-induced renal 
injury. This finding strengthens the rationale of CONVERT study 
that the effectiveness of SRL is dependent upon the status of 
graft function. 
  We further evaluated the influence of SRL conversion at the 
molecular level. In experimental models of chronic CsA nephrop-
athy, CsA-induced renal injury recruits macrophages, and this 
recruitment is mediated by several proinflammatory cytokines 
(13, 20). OPN is proinflammatory mediator, and chronic CsA 
treatment increases OPN concentration in rat models (14-16). 
The CsA-induced renal injury also upregulates the expression 
of active caspase-3 and leads to apoptotic cell death (17, 18). In 
our current study, early conversion to SRL did not change mac-
rophage infiltration and OPN protein expression after CsA with-
drawal. However late conversion to SRL potentiated macrophage 
infiltration and OPN expression even after CsA withdrawal. In 
addition, early but late conversion to SRL increased the active 
caspase-3 expression and the number of TUNEL-positive cells 
compared with the CsA withdrawal group. This finding confirms 
the idea that early conversion to SRL is beneficial for attenuat-
ing CsA-induced inflammation and apoptotic cell death.
  We used an experimental model of chronic CsA nephropa-
thy, but our model has some limitations when translated into 
clinical practice. First, CsA trough levels were much higher than 
those targeted in clinical practice. Second, our experimental 
model of chronic CsA nephropathy produces minimal protein-
uria, and we could not observe influence of SRL on proteinuria. 
Third, a follow-up period for 8 weeks has been better for defin-
ing the relationship between CsA and SRL groups in experiment 
III. However, the study period could not be extended, because 
rats cannot survive beyond 4 weeks under high dose CsA (15 
mg/kg) and low salt diet. Therefore, the results of our study should 
be translated cautiously to clinical practice.
  In conclusion, the results of our study provide a theoretical 
basis for a CsA sparing strategy using SRL and that it is desirable 
to convert SRL from calcineurin inhibitors before development 
of chronic CsA nephrotoxicity. 
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